drugset / Trial / NCT00004380
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
Phase 2
Completed
1 enrolled
National Center for Research Resources (NCRR)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collabStanford University · collab
Non-randomizedTreatment
Summary
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.
Timeline
- Start
- 1991-12
- Primary completion
- —
- Completion
- 1997-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relaxin | Protein / enzyme biologic | — | Subcutaneous |